Exponent, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXPO research report →
Range $72 – $72
Price Chart
About the company
Exponent, Inc. functions as a global leader in scientific and engineering consulting, operating through its subsidiaries. The firm's activities are divided into two principal segments: Engineering and Other Scientific, and Environmental and Health.
- CEO
- Catherine Ford Corrigan
- IPO
- 1990
- Employees
- 1,016
- HQ
- Menlo Park, CA, US
Get TickerSpark's AI analysis on EXPO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.24B
- P/E
- 38.41
- Fwd P/E
- 37.80
- PEG
- 2.92
- P/S
- 6.43
- P/B
- 13.93
- EV/EBITDA
- 26.63
- Div Yield
- 1.38%
- Gross Margin
- 25.50%
- Op Margin
- 21.31%
- Net Margin
- 17.40%
- ROE
- 34.61%
- ROIC
- 19.41%
Latest fiscal year · YoY change
- Revenue
- $582.01M+4.2%
- Gross Profit
- $145.31M+2.1%
- Op Income
- $119.79M
- Net Income
- $106.01M-2.7%
- EPS
- $2.08-2.3%
- OCF Growth
- -8.9%
- FCF Growth
- -11.1%
- 52W High
- $90.97
- 52W Low
- $51.91
- 50D MA
- $74.96
- 200D MA
- $67.50
- Beta
- 0.68
- RSI (14)
- 76
- Avg Volume
- 514.66K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Exponent delivered a strong third quarter with double-digit revenue and earnings growth, and it raised full-year net revenue and margin guidance on continued demand in user research, disputes, and AI-related work.· October 29, 2026
- Q3 total revenue rose 18% to $173.7 million; net revenue rose 12% to $153.1 million.
- Diluted EPS increased 16% to $0.64, and net income rose 10% to $30.9 million.
- EBITDA increased 16% to $45 million, with margin expanding to 29.4% of net revenues.
- Management raised full-year 2026 guidance for net revenue growth to 10% to 11% and EBITDA margin to 28% to 28.3%.
- AI-related work is now estimated to be a direct element of roughly 15% to 20% of the business this year, with management seeing more projects emerging across the stack.
Third quarter 2026 total revenue increased 18% year over year to $173.7 million, while net revenue increased 12% to $153.1 million. Net income rose 10% to $30.9 million, and diluted EPS increased 16% to $0.64 versus $0.55 a year ago. EBITDA increased 16% to $45 million, representing 29.4% of net revenues versus 28.3% last year. Billable hours increased 8% year over year to approximately 405,000, utilization improved to 76.7% from 74.1%, and the realized rate increase was about 4%. For the fourth quarter of 2026, Exponent expects net revenue growth of 8% to 10% and EBITDA margin of 26.3% to 26.8% of net revenues. For full-year 2026, it now expects net revenue growth of 10% to 11% and EBITDA margin of 28% to 28.3% versus 27.6% in 2025. It also expects full-year utilization of 73.5% to 74%, realized rate increases of 3.7% to 4%, stock-based compensation of $28.1 million to $28.4 million, other operating expenses of $53 million to $53.5 million, G&A of $28.1 million to $28.6 million, and capital expenditures of $10 million to $12 million.
Catherine Corrigan framed the quarter as evidence of Exponent’s differentiation in the convergence of technology, infrastructure, and human behavior. She said demand is being driven by harder questions around safety, reliability, product performance, and real-world AI applications, and noted that the company’s integrated teams are well suited to those problems. Her tone was confident and upbeat, emphasizing long-term growth, talent investments, and broadening opportunities across both proactive and reactive work.
Eric Anderson highlighted strong year-over-year growth across the income statement and operating metrics, including 18% revenue growth, 12% net revenue growth, 16% EBITDA growth, and 16% EPS growth. He noted the quarter benefited from higher utilization, a 4% realized rate increase, and 1,016 average technical FTEs, up 4% year over year; compensation expense rose 11% after deferred compensation adjustments, while other operating expenses rose 9% and G&A declined 4%. On capital allocation, he said the company used $171 million for repurchases over the past 12 months, did not repurchase stock in Q3, paid $14.7 million in dividends, spent $1.2 million on capex in the quarter, and still has $50 million authorized for repurchases.
Analysts focused on the unusually strong utilization rate, asking whether it reflected structural productivity or calendar effects. Management said it was mainly broad-based demand, not calendar timing, with strength in disputes and better-than-expected proactive work; a project that was 4% of revenue in Q2 fell to 2.5% in Q3 and is expected to drop under 1% in Q4. Questions also centered on AI: management said AI-related work is already showing up in both proactive and reactive engagements, especially in transportation, data centers, wearable/medical device applications, and construction disputes, while full litigation-scale cases are still early. Analysts also pressed on hiring and pricing, and management said it is leaning into recruiting across human factors, biomechanics, thermal science, polymers, metallurgy, energy storage, and environmental/chemical specialties, while buybacks should continue opportunistically alongside dividends and possible small acquisitions.
The call suggested Exponent is seeing broad, durable demand across both proactive and reactive work, with user research, disputes, failure analysis, and product safety all contributing. Management also sees AI becoming a larger driver of work, estimating it directly touches 15% to 20% of the business this year and expecting continued growth as AI moves into physical products and systems.
Management acknowledged that fourth-quarter growth will slow versus Q3 on a tough comp and seasonal utilization pressure, with Q4 utilization expected to fall to 69% to 70%. The Environmental and Health segment grew only 3% in Q3, and management said reacceleration depends on continued senior recruiting and capability-building. They also noted the AI-related dispute pipeline is still early, so some of the most visible opportunities may take time to become larger litigation or regulatory matters.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.7%
- Shares Outstanding
- 47.55M
- Float Shares
- 46.93M
of shares held by institutions
347 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for EXPO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Sep 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Aug 13, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Buy | Mar 13, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Buy | Feb 24, 25 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Dec 16, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.21M | ▲ 23.36K |
| Vanguard Group Inc | 5.14M | ▼ 107.74K |
| Kayne Anderson Rudnick Investment Management LLC | 3.29M | ▼ 701.45K |
| Vanguard Portfolio Management LLC | 3.09M | ▼ 53.39K |
| Vanguard Capital Management LLC | 2.10M | ▼ 79.50K |
| State Street Corp | 1.96M | ▲ 13.93K |
| Geode Capital Management, LLC | 1.77M | ▲ 22.29K |
| Morgan Stanley | 1.32M | ▲ 107.58K |
| Geneva Capital Management LLC | 1.28M | ▼ 120.28K |
| Royce & Associates LP | 1.24M | ▼ 84.03K |
| First Trust Advisors LP | 1.16M | ▲ 78.69K |
| Aqr Capital Management LLC | 1.14M | ▲ 163.57K |
Held by 401 ETFs
Biggest fund positions in EXPO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Reiss Richard | sell | 1,280 |
| Sep 18, 26 | Souri Shukri Jeries | buy | 184 |
| Sep 4, 26 | Souri Shukri Jeries | other | 0 |
| Mar 13, 30 | Souri Shukri Jeries | other | 0 |
| Mar 15, 28 | Souri Shukri Jeries | other | 0 |
| Mar 14, 29 | Souri Shukri Jeries | other | 0 |
| Mar 10, 27 | Souri Shukri Jeries | other | 0 |
| Aug 17, 26 | Corrigan Catherine | other | 2,379 |
| Aug 17, 26 | Corrigan Catherine | sell | 1,707 |
| Aug 17, 26 | Corrigan Catherine | other | 2,379 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EXPO coverage
Recent articles, reports, and earnings notes.
No research on EXPO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EXPO report →Exponent, Inc. (EXPO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
What Exponent (EXPO) Said on Its Q3 Earnings Call
marketbeat.com · Oct 29
Exponent (EXPO) Tops Q3 Earnings and Revenue Estimates
zacks.com · Oct 29
Exponent Q3 2026 Earnings Call Transcript
benzinga.com · Oct 29
Exponent Reports Third Quarter 2026 Financial Results
globenewswire.com · Oct 29
Exponent Declares Regular Quarterly Dividend for Q4 2026
globenewswire.com · Oct 29
Is Exponent (EXPO) Stock Outpacing Its Business Services Peers This Year?
zacks.com · Oct 19
Corient Private Wealth LP Trims Stake in Exponent, Inc. $EXPO
defenseworld.net · Oct 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.